Full-Time

Pioneering Medicines: DMPK Project Leader

Posted on 8/5/2024

Flagship Pioneering

Flagship Pioneering

201-500 employees

Biotechnology firm creating health and sustainability solutions

No salary listed

Senior, Expert

Cambridge, MA, USA

Category
Computational Biology
Public Health
Biology Lab & Research
Biology & Biotech
Requirements
  • Ph.D. in pharmaceutical science, biochemistry, or related scientific discipline wit 7+ years or MS/BS with 10+years of relevant experience
  • 5+ years experience leading representing DMPK function on project teams, particularly in discovery and early development is required.
  • Extensive knowledge of drug metabolism, PK, and relevant analytical techniques is required.
  • Strong understanding of small molecule drug discovery workflow is required; understanding of biologics/novel modalities is desirable.
  • Hands on experience conducting, troubleshooting, and summarizing in vitro and in vivo ADME/DMPK studies is required.
  • Familiarity with regulatory guidelines and requirements related to DMPK in drug development is desirable.
  • Demonstrated DMPK skills through high quality peer-reviewed publications is desirable.
  • Experience in outsourcing and external oversight of nonclinical DMPK/ADME studies is desirable.
  • Attention to detail and quality are critical to success.
  • Excellent communication skills including interpersonal skills and data presentation skills.
  • Demonstrated ability to adapt to a fast-paced and dynamic work environment.
  • Demonstrated ability to successfully work in cross-functional teams with an emphasis on teamwork, collaboration, and communication within team and across the department.
  • Forward thinking mindset with demonstrated ability to manage multiple projects and identify and resolve issues.
Responsibilities
  • Represent the DMPK function on cross-functional discovery teams and provide technical and scientific expertise for ADME profiling and interpretation of the data.
  • Define strategy for in vitro/in vivo DMPK and DDI risk assessment for drug candidates.
  • Strategically design and lead ADME/PK studies, critically analyze and interpret data, identify issues, and help overcome technical challenges.
  • Coordinate and interact with matrix project team members for planning and executing DMPK-related activities.
  • Collaborate with PK/PD modelers to establish PK/PD correlations and guide preclinical study design.
  • Contribute to the selection of preclinical tox species and toxicokinetic plan to support IND.
  • Support human dose projections based on preclinical data to guide candidate selection.
  • Author ADME/DMPK sections of regulatory documents (e.g., IND/IB).
  • Contribute to the development of functional processes and procedures focused on CRO interactions and organizational efficiency.
  • Conduct scientific presentations to senior management, project teams, and internal/external collaborators.
  • Provide operational oversight for quality and performance of DMPK activities, including interactions with CROs and external project support.
  • Contribute to the selection and qualification of CROs and vendors.
  • Closely interact with key internal stakeholders and Flagship ecosystem companies.

Flagship Pioneering fosters a culture of groundbreaking advancements in biotechnology, emphasizing an ecosystem approach that synergizes human health and sustainability. Their business model not only focuses on creating transformative products but also incubates leading companies like Moderna and Indigo Agriculture, positioning them at the forefront of scientific innovation and industry leadership. This approach offers employees a unique opportunity to be part of a pioneering team that drives real-world impacts across multiple sectors.

Company Size

201-500

Company Stage

N/A

Total Funding

$10.5B

Headquarters

Cambridge, Maryland

Founded

2000

Simplify Jobs

Simplify's Take

What believers are saying

  • AI-driven drug discovery complements Flagship's ventures in AI and robotics.
  • Synthetic biology aligns with Flagship's focus on transformative biological innovations.
  • Digital health platforms support Flagship's ventures in remote health technologies.

What critics are saying

  • Increased competition in AI-driven scientific discovery may reduce differentiation.
  • Potential overvaluation in agtech could lead to market corrections and instability.
  • Dependence on academic collaborations may risk if expected advancements aren't achieved.

What makes Flagship Pioneering unique

  • Flagship Pioneering systematically creates first-in-category companies in health and sustainability.
  • The firm combines innovative capacity with entrepreneurial leadership and capital management.
  • Flagship's evolutionary methodology transforms unreasonable propositions into transformational outcomes.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Flexible Work Hours

Company News

GlobeNewswire
Mar 19th, 2025
Ampersand Biomedicines Raises Series B Financing and Highlights Pipeline Advancements

$65 million in Series B funding secured from investors, including founder Flagship Pioneering and Eli Lilly & Company Two lead programs in...

BioPharmaTrend
Mar 11th, 2025
Lila Sciences Raises $200M to Automate Scientific Discovery with AI and Robotics

Flagship Pioneering has announced the launch of Lila Sciences, a company developing an AI-based platform designed to automate scientific experimentation and discovery.

PR Newswire
Mar 10th, 2025
Flagship Pioneering Unveils Lila Sciences to Build Superintelligence in Science

/PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today unveiled Lila Sciences, a company building the world's first scientific...

ABL Advisor
Mar 3rd, 2025
Trinity Capital Expands Life Sciences Presence to East Coast, Appoints Orlando as Managing Director

Trinity Capital announced the appointment of John Orlando as Managing Director of Life Sciences, based in Boston.

Contract Pharma
Feb 19th, 2025
YourBio Health Taps Paul Owen as CEO

Paul Owen has been appointed as Chief Executive Officer of YourBio Health, a pioneer in remote blood collection technology, and CEO-Partner of Flagship Pioneering, a bioplatform innovation company.

INACTIVE